



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/719,410	
	Filing Date	December 12, 2000	
	First Named Inventor	GOKE et al.	
	Group Art Unit		
	Examiner Name		
Total Number of Pages in This Submission	5	Attorney Docket Number	0206-UTL-9

TECH CENTER 1600 2900

JUN 18 2003


RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Molly A. Holman
Signature	
Date	June 12, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: 6/12/03			
Typed or printed name	Cassandra Peters		
Signature		Date	June 12, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GOKE *et al.*

Appln. No.: 09/719,410

Int'l Filing

Date: December 12, 2000

For: GLUCAGON-LIKE PEPTIDE-1
IMPROVES BETA-CELL
RESPONSE TO GLUCOSE IN
SUBJECTS WITH IMPAIRED
GLUCOSE TOLERANCE

Art Unit:

Examiner:

AMYLIN

Docket No. 0206-UTL-9

TECH CENTER 1600/2900

JUN 18 2003

RECEIVED

**Revocation of Prior Power of Attorney,
Appointment of New Attorneys of Record and
Change of Correspondence Address**

Commissioner for Patents,
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Amylin Pharmaceuticals, Inc. is the assignee of the entire right, title and interest in the above-identified application by virtue of the assignment executed on January 29, 2003 and sent for recordation to the U.S. Patent and Trademark Office on February 4, 2003 (please see attached copies). The undersigned, having express authority to represent Amylin Pharmaceuticals, Inc. as assignee, hereby revokes all powers of attorney heretofore given in the above-captioned application and appoints the attorneys and agents listed below with full power of substitution, association, and revocation, to prosecute said application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Matthew N. Bathon, Reg. No. 51,441
Timothy C. Bickham, Reg. No. 41,618
June E. Cohan, Reg. No. 43,741
Danielle M. Edwards, Reg. No. 51,645
James R. Farrand, Reg. No. 38,136
Joel M. Freed, Reg. No. 25,101
Dawn M. Gardner, Reg. No. 44,118
Leslie M. Hill, Reg. No. 51,805
Leslie L. Jacobs, Jr., Reg. No. 40,659
Kristan L. Lansbery Reg. No. 53,183
Stanton T. Lawrence, III Reg. No. 25,736
David R. Marsh, Reg. No. 41,408

Joseph Micallef, Reg. No. 39,772
Lisa A. Penoyer, Reg. No. 51,204
Holly Logue Prutz, Reg. No. 47,755
Joseph W. Ricigliano, Reg. No. 48,511
Sidney A. Rosenzweig, Reg. No. 43,893
William Sekyi, Reg. No. 45,831
Ali R. Sharifahmadian, Reg. No. 48,202
Michael J. Songer, Reg. No. 39,841
Marcia Sundeen, Reg. No. 30,893
Milan M. Vinnola, Reg. No. 45,979
Todd A. Wagner, Reg. No. 35,399
Bryan Webster, Reg. No. 47,214
Robert Jones Worrall, Reg. No. 37,969
Paul Zegger, Reg. No. 33,821,

all of Arnold & Porter, and

Molly A. Holman, Reg. No. 40,022
Mi K. Kim, Reg. No. 44,830

Joanna L. Moore, Reg. No. 44,950,

all of Amylin Pharmaceuticals, Inc.

Please address future correspondence to

ARNOLD & PORTER
Attn: IP Docketing Department, Room 1126B
555 Twelfth Street, NW
Washington, DC 20004-1206

Telephone calls should be directed to David R. Marsh, (202) 942-5000 and facsimile transmissions to (202) 942-5999.


FOR: Amylin Pharmaceuticals, Inc.

SIGNATURE: 

BY: Lloyd A. Rowland

TITLE: Vice President and General Counsel

DATE: 6/10/03



RECORDATION FORM COVER SHEET PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

BioNebraska, Inc., a/k/a Restoragen, Inc.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

Execution Date: January 29, 2003

2. Name and address of receiving party(ies)

Name: Amylin Pharmaceuticals, Inc.

Internal Address:

Street Address: 9373 Towne Centre Drive

City: San Diego State: CA Zip: 92121

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

60/089,044

09/719,410

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Edmund J. Sease

Internal Address:

Street Address: 801 Grand, Suite 3200

City: Des Moines State: IA Zip: 50309-2721

6. Total number of applications and patents involved:

2

7. Total fee (37 CFR 3.41).....\$ 80.00

☒ Enclosed [Please charge any deficiency or credit any overpayment to Deposit Account No. 26-0084]

☐ Authorized to be charged to deposit account

8. Deposit account number:

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Edmund J. Sease

Name of Person Signing

Edmund J. Sease
Signature

February 4, 2003

Date

Total number of pages including cover sheet, attachments, and document:

3

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents & Trademarks, Box Assignments

Washington, D.C. 20231

RECEIVED

JUN 18 2003

TECH CENTER 1600/2900

ASSIGNMENT OF PATENTS, PENDING APPLICATIONS AND FOREIGN
EQUIVALENTS

In consideration of One Dollar and other good and valuable considerations, the receipt and sufficiency whereof are hereby acknowledged, the undersigned **BioNebraska, Inc., also known as Restoragen, Inc.**, a Delaware corporation, having an address of 5701 South 34th Street, Suite 203, Lincoln, Nebraska 68516, hereby assigns to **Amylin Pharmaceuticals, Inc.**, a Delaware corporation, having an address of 9373 Towne Centre Drive, San Diego, California 92121, its successors and assigns the entire right, title and interest in the invention or improvements of the undersigned disclosed in the following applications for Letters Patent of the United States:

<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
60/089,044	6/12/1998	Glucagon-Like Peptide-1 Improves the Ability Of the β -Cell To Sense And Respond To Glucose In Subjects With Impaired Glucose Tolerance
09/719,410	12/12/2000	Glucagon-Like Peptide-1 Improves Beta-Cell Response To Glucose In Subjects With Impaired Glucose Tolerance

and in said applications and any and all other priority or related patents or applications for patents worldwide, which the undersigned has filed or may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent applications, and in any reissue or extension thereof, and in any and all foreign equivalents thereof.

The undersigned hereby authorizes and requests the Commissioner of Patents to issue said United States Letters Patent to said **Amylin Pharmaceuticals, Inc.**

For said considerations the undersigned hereby agrees, upon the request, and at the expense of said Assignee, its successors and assigns, to execute any and all divisional, continuation and substitute applications for said invention or improvements, and any necessary oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon said application, and for the said considerations the undersigned further agrees upon the request of said Assignee, its successors or assigns, in the event of any application or Letters Patent assigned herein becoming involved in interference, to cooperate to the best of the ability of the undersigned with said Assignee, its successors or assigns in the

matters of preparing and executing the preliminary statement and giving and producing evidence in support thereof, the undersigned hereby agreeing to perform, upon request, any and all affirmative acts to obtain said Letters Patent of the United States and vest all rights therein hereby conveying in the said Assignee, its successors and assigns whereby said Letters Patent will be held and enjoyed by the said Assignee, its successors and assigns to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment and sale had not been made.

And for said considerations the undersigned hereby assigns to said Assignee, its successors and assigns, the entire right, title and interest in said inventions or improvements for any and all foreign countries and agrees upon the request of Assignee, its successors and assigns to execute any and all documents that undersigned shall be requested to execute in connection with any and all applications for foreign Letters Patent therefor, including the prosecution thereof, and to execute any and all documents necessary to vest title in said foreign applications and patents in Assignee.


BIONE BRASKA, INC.


Ashleigh Palmer
Chief Executive Officer

State Of New Jersey)
) ss.
County Of _____)

On this 29 day of January, 2003, before me, a Notary Public in and for the County and State the aforesaid, appeared Ashleigh Palmer, to me personally known to be the person whose name is subscribed to the foregoing instrument, and acknowledged that he executed said instrument as his free and voluntary act for the uses and purposes therein expressed.

Witness my hand and seal the day and year last above given.


Notary Public
Commission Expires July 11, 2005

JODY J. KRAZER
NOTARY PUBLIC OF NEW JERSEY
MY COMMISSION EXPIRES JULY 11, 2005